Pharmaceuticals, Biotechnology and Life Sciences
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage…
Italian Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, and Japanese EA Pharma, a subsidiary of Eisai Co., Ltd., have entered into a license agreement to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated Asian territories.
Each unit is being sold at an effective offering price of $5.85 per unit, priced at-the-market under Nasdaq rules.
BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) — LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a leading…
US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade
In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated…
Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) — Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter…
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused…
No impact at this time on the listing of the Company’s Ordinary Shares on NasdaqCompany intends to submit to Nasdaq…
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is…